Merck KGaA has announced that the Phase IIIb SPARK study of Kuvan (sapropterin dihydrochloride) added to a phenylalanine-restricted diet in...
Merck Serono has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...
BioMarin Pharmaceutical has announced that it has acquired all global rights to Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono....
Merck KGaA/Merck Serono has announced that the European Commission (EC) has authorized a change to the European marketing authorization for...